XML 87 R82.htm IDEA: XBRL DOCUMENT v2.4.0.8
Investments in Variable Interest Entities (Details) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Dec. 31, 2012
Investment in Variable Interest Entities (Textual) [Abstract]          
Research and development $ 410,017,000 $ 304,217,000 $ 1,021,820,000 $ 989,738,000  
Investment in biotechnology companies that are determined to be unconsolidated variable interest entities 6,800,000   6,800,000   9,400,000
Knopp [Member]
         
Investment in Variable Interest Entities (Textual) [Abstract]          
Percentage of funding for R&D cost required in support of the collaboration agreement     100.00%    
Research and development   15,700,000   58,900,000  
Neurimmune [Member]
         
Investment in Variable Interest Entities (Textual) [Abstract]          
Percentage of funding for R&D cost required in support of the collaboration agreement     100.00%    
Research and development 6,100,000 3,400,000 16,800,000 8,500,000  
Remaining potential development milestone payments and royalties on commercial sales under the terms of collaboration agreement     $ 345,000,000    
Common Class B [Member] | Knopp [Member]
         
Investment in Variable Interest Entities (Textual) [Abstract]          
Purchase of common shares in variable interest entities     30.00%